Frank Lewis Brodie, MD
Ophthalmology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 2
- Since medical school
- 12 years
- Perelman School of Med at the University of Pennsylvania, 2014
Offices
2 locations · UCSF Medical Group Business Services · 1,533 clinicians in this group
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Brodie’s office at (510) 985-5020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A137610 · Current
Licensed to practise in California · since 2015 · expires 2027-01-31 · Perelman School of Medicine at the University of Pennsylvania.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$45,126
Medicare paid this office $45,126 for 133 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection of drug into eye | 37 | $11,124 | $96 |
| Established patient complete exam of visual system | 71 | $6,666 | $68 |
| Imaging of retina | 97 | $4,623 | $23 |
| Injection of drug into eye | 33 | $4,589 | $68 |
| Established patient complete exam of visual system | 45 | $2,574 | $50 |
See all 6 services
| Injection of drug into eye | 37 | $11,124 | $96 |
| Established patient complete exam of visual system | 71 | $6,666 | $68 |
| Imaging of retina | 97 | $4,623 | $23 |
| Injection of drug into eye | 33 | $4,589 | $68 |
| Established patient complete exam of visual system | 45 | $2,574 | $50 |
| Imaging of retina | 66 | $1,765 | $16 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | – | – | 30 | 116 | 174 | 183 |
| Removal of eye fluid (vitreous) between lens and retina | – | 11 | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
133 Original Medicare patients in 2024. Average age 76 · Women 56% · Also on Medicaid 32% · Health risk score 1.59. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 68% · Diabetes 35% · Chronic kidney disease 29% · Coronary heart disease 24% · Depression 22% · Cancer 20% · Atrial fibrillation 19% · Heart failure 17% · Stroke 8%.
The office billed $481,566, Medicare allowed $61,845 and paid $45,126; for 709 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 133 | 709 | 76 | 1.59 | $481,566 | $45,126 |
| 2023 | 178 | 923 | 75 | 1.70 | $609,658 | $60,309 |
| 2022 | 162 | 847 | 75 | 1.48 | $559,232 | $59,312 |
| 2021 | 115 | 365 | 72 | 1.43 | $171,932 | $20,019 |
| 2020 | 60 | 100 | 70 | 1.75 | $56,298 | $8,087 |
| 2019 | 51 | 71 | 69 | 1.56 | $49,673 | $8,138 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Established patient complete exam of visual system | 149 | $14,748 | $63 |
| Injection of drug into eye | 43 | $12,526 | $72 |
| Imaging of retina | 162 | $8,618 | $21 |
| New patient complete exam of visual system | 16 | $1,290 | $81 |
2022: 7 services
| Established patient complete exam of visual system | 110 | $11,714 | $68 |
| Injection of drug into eye | 36 | $9,249 | $80 |
| Imaging of retina | 157 | $8,209 | $22 |
| New patient complete exam of visual system | 38 | $3,211 | $84 |
| Short return visit (20+ min) | 11 | $654 | $59 |
| Established patient problem focused exam of visual system | 16 | $651 | $36 |
| Extended exam of the back part of the eye with retinal drawing | 20 | $354 | $18 |
2021: 6 services
| New patient complete exam of visual system | 34 | $2,984 | $88 |
| Imaging of retina | 85 | $2,937 | $25 |
| Injection of drug into eye | 16 | $2,626 | $88 |
| Established patient complete exam of visual system | 19 | $1,435 | $76 |
| Established patient problem focused exam of visual system | 18 | $1,024 | $47 |
| Extended exam of the back part of the eye with retinal drawing | 30 | $689 | $22 |
2020: 3 services
| Removal of eye fluid (vitreous) between lens and retina | 11 | $1,229 | $112 |
| Established patient problem focused exam of visual system | 13 | $768 | $55 |
| Imaging of retina | 18 | $504 | $28 |
2019: 1 service
| Imaging of retina | 15 | $467 | $31 |
Medicaid work
$8,739 in 2024
Medicaid paid $8,739 for 78 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 15 | $6,483 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 49 | $1,324 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 14 | $932 |
| 2024 | 78 | 3 | 19 | $8,739 |
| 2023 | 235 | 2 | 21 | $10,256 |
| 2022 | 92 | 1 | 21 | $2,014 |
| 2021 | 15 | 1 | 15 | $347 |
See the largest Medicaid services in earlier years
2023
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 80 | $6,170 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 155 | $4,085 |
2022
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 92 | $2,014 |
2021
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 15 | $347 |
Drugs they prescribed that Part D paid
$8,060
Pharmacies billed $8,060 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 131) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
93 generic and 38 brand-name prescriptions · $8,060 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 19 | $1,262 | $66 |
| Brimonidine | 11 | $617 | $56 |
| Atropine Sulfate | 12 | $413 | $34 |
| Ketorolac Tromethamine | 16 | $318 | $20 |
| Dorzolamide-Timolol | 16 | $160 | $10 |
See all 6 drugs
| Prednisolone Acetate | 19 | $1,262 | $66 |
| Brimonidine | 11 | $617 | $56 |
| Atropine Sulfate | 12 | $413 | $34 |
| Ketorolac Tromethamine | 16 | $318 | $20 |
| Dorzolamide-Timolol | 16 | $160 | $10 |
| Latanoprost | 13 | $117 | $9 |
Year by year
| 2024 | 131 | 34 | 0% (0) | 29% | $8,060 |
| 2023 | 164 | 43 | 0% (0) | 38% | $11,597 |
| 2022 | 174 | 54 | None | 30% | $9,309 |
| 2021 | 571 | 175 | 0% (0) | 43% | $40,150 |
| 2020 | 605 | 197 | 0% (0) | 40% | $57,228 |
| 2019 | 250 | 96 | None | 42% | $11,852 |
| 2018 | 69 | 18 | 0% (0) | 29% | $4,409 |
| 2017 | 195 | 64 | 0% (0) | 41% | $13,585 |
| 2016 | 193 | 36 | 0% (0) | 48% | $13,782 |
| 2015 | 16 | None | 0% (0) | None | $1,192 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Prednisolone Acetate | 30 | $1,772 | $59 |
| Atropine Sulfate | 16 | $1,096 | $68 |
| Ketorolac Tromethamine | 20 | $846 | $42 |
| Dorzolamide-Timolol | 18 | $419 | $23 |
| Brimonidine | 13 | $209 | $16 |
| Latanoprost | 16 | $202 | $13 |
2022: 6 drugs
| Prednisolone Acetate | 34 | $2,344 | $69 |
| Atropine Sulfate | 23 | $1,782 | $77 |
| Timolol Maleate | 13 | $1,278 | $98 |
| Dorzolamide-Timolol | 24 | $553 | $23 |
| Polymyxin B Sul-Trimethoprim | 17 | $139 | $8 |
| Brimonidine | 13 | $128 | $10 |
2021: 12 drugs
| Durezol | 31 | $7,951 | $256 |
| Prednisolone Acetate | 115 | $6,148 | $53 |
| Atropine Sulfate | 52 | $3,048 | $59 |
| Ketorolac Tromethamine | 55 | $2,367 | $43 |
| Brimonidine | 23 | $1,661 | $72 |
| Dorzolamide-Timolol | 55 | $1,130 | $21 |
| Valacyclovir | 11 | $983 | $89 |
| Ofloxacin | 38 | $811 | $21 |
| Erythromycin | 45 | $536 | $12 |
| Dorzolamide | 16 | $423 | $26 |
| Latanoprost | 21 | $321 | $15 |
| Timolol Maleate | 25 | $264 | $11 |
2020: 12 drugs
| Prednisolone Acetate | 116 | $6,237 | $54 |
| Ketorolac Tromethamine | 107 | $4,590 | $43 |
| Atropine Sulfate | 41 | $2,290 | $56 |
| Brimonidine | 18 | $2,144 | $119 |
| Dorzolamide-Timolol | 34 | $1,580 | $46 |
| Ofloxacin | 36 | $817 | $23 |
| Erythromycin | 41 | $525 | $13 |
| Dorzolamide | 12 | $361 | $30 |
| Timolol Maleate | 20 | $350 | $17 |
| Latanoprost | 17 | $170 | $10 |
| Gentamicin Sulfate | 13 | $147 | $11 |
| Prednisone | 20 | $121 | $6 |
2019: 5 drugs
| Prednisolone Acetate | 59 | $2,371 | $40 |
| Atropine Sulfate | 27 | $1,453 | $54 |
| Ofloxacin | 42 | $1,273 | $30 |
| Erythromycin | 44 | $496 | $11 |
| Ketorolac Tromethamine | 12 | $433 | $36 |
2018: 2 drugs
| Brimonidine | 17 | $2,130 | $125 |
| Timolol Maleate | 19 | $222 | $12 |
2017: 6 drugs
| Alphagan P | 11 | $3,139 | $285 |
| Brimonidine | 20 | $1,497 | $75 |
| Prednisolone Acetate | 27 | $1,458 | $54 |
| Latanoprost | 39 | $826 | $21 |
| Timolol Maleate | 39 | $452 | $12 |
| Dorzolamide | 16 | $340 | $21 |
2016: 5 drugs
| Brimonidine | 46 | $3,579 | $78 |
| Travatan Z | 14 | $2,727 | $195 |
| Dorzolamide | 35 | $795 | $23 |
| Latanoprost | 28 | $491 | $18 |
| Timolol Maleate | 20 | $170 | $9 |
Money from drug and device companies
$13,164 in 2025
| 2025 | 12 | 31 | $11,750 | $13,164 |
| 2024 | 14 | 42 | $16,966 | $19,324 |
| 2023 | 9 | 31 | $10,450 | $13,908 |
| 2022 | 5 | 10 | None | $356 |
| 2021 | 4 | 7 | None | $695 |
| 2020 | 5 | 5 | $350 | $613 |
| 2019 | 6 | 14 | None | $2,588 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| F. Hoffmann-La Roche AG | None | $4,810 | 4 payments
|
| Genentech USA | Susvimo | $4,218 | 8 payments
|
| Tarsus Pharmaceuticals | None | $2,380 | 2 payments
|
| Genentech | Susvimo | $575 | 1 payment
|
| Alcon Vision | Constellation | $331 | 5 payments
|
| Alcon Research | None | $300 | 1 payment
|
See all 31 published payments
| F. Hoffmann-La Roche AG | Consulting · 2025-12-04 | None | $2,925 |
| F. Hoffmann-La Roche AG | Meals · 2025-12-04 | None | $27 |
| Abbvie | Meals · 2025-12-03 | Ozurdex | $37 |
| Alcon Research | Meals · 2025-10-17 | None | $300 |
| Genentech USA | Meals · 2025-09-23 | Vabysmo | $33 |
| Alcon Vision | Meals · 2025-09-06 | Unity | $64 |
| Astellas Pharma US | Meals · 2025-08-21 | Izervay | $27 |
| Astellas Pharma US | Meals · 2025-08-01 | Izervay | $75 |
| Dutch Ophthalmic USA | Meals · 2025-07-31 | Eva, Combined Machine | $149 |
| Alcon Vision | Meals · 2025-07-30 | Constellation | $162 |
| Genentech USA | Meals · 2025-07-30 | Susvimo | $33 |
| ANI Pharmaceuticals | Meals · 2025-07-11 | Yutiq | $32 |
| Regeneron Healthcare Solutions | Meals · 2025-07-10 | Eylea Hd | $26 |
| Astellas Pharma US | Meals · 2025-06-26 | Izervay | $101 |
| Tarsus Pharmaceuticals | Consulting · 2025-06-23 | None | $2,375 |
| Alcon Vision | Meals · 2025-06-14 | Unity | $26 |
| Alcon Vision | Meals · 2025-06-14 | Unity | $43 |
| Genentech USA | Meals · 2025-06-04 | Vabysmo | $27 |
| Abbvie | Meals · 2025-05-28 | Ozurdex | $24 |
| F. Hoffmann-La Roche AG | Meals · 2025-05-05 | None | $58 |
| F. Hoffmann-La Roche AG | Consulting · 2025-05-05 | None | $1,800 |
| Genentech USA | Consulting · 2025-04-25 | Susvimo | $2,925 |
| Genentech | Consulting · 2025-04-08 | Susvimo | $575 |
| Tarsus Pharmaceuticals | Meals · 2025-04-03 | None | $5 |
| Genentech USA | Meals · 2025-03-27 | Susvimo | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-03-17 | Eylea Hd | $25 |
| Genentech USA | Meals · 2025-03-13 | Vabysmo | $26 |
| Bausch & Lomb Americas | Meals · 2025-03-11 | Xipere | $54 |
| Alcon Vision | Meals · 2025-01-15 | Constellation | $36 |
| Genentech USA | Consulting · 2025-01-09 | Susvimo | $575 |
| Genentech USA | Consulting · 2025-01-09 | Susvimo | $575 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $19,324
| Abbvie | Ozurdex | $6,574 | 6 payments
|
| Tarsus Pharmaceuticals | None | $4,750 | 2 payments
|
| Genentech USA | Susvimo | $2,990 | 10 payments
|
| Apellis Pharmaceuticals | Syfovre | $1,994 | 3 payments
|
| Bausch & Lomb Americas | Miebo | $1,490 | 4 payments
|
| Alcon Vision | Constellation | $517 | 4 payments
|
| Harrow Eye | Iheezo | $349 | 3 payments
|
| Genentech | Vabysmo | $190 | 2 payments
|
| Carl Zeiss Meditec | Veracity Surgical | $168 | 1 payment
|
| Dutch Ophthalmic USA | Eva, Combined Machine | $166 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea Hd | $49 | 2 payments
|
| Astellas Pharma US | Izervay | $33 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $28 | 2 payments
|
| Alimera Sciences | Yutiq | $27 | 1 payment
|
2023: $13,908
| Genentech USA | Vabysmo | $10,096 | 8 payments
|
| Genentech | Susvimo | $2,509 | 3 payments
|
| Dutch Ophthalmic USA | Eva, Combined Machine | $568 | 4 payments
|
| Bausch & Lomb Americas | Xipere | $275 | 5 payments
|
| AbbVie | Ozurdex | $224 | 3 payments
|
| Alimera Sciences | Yutiq | $102 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $58 | 2 payments
|
| Astellas Pharma US | None | $56 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $20 | 1 payment
|
2022: $356
| Regeneron Healthcare Solutions | Eylea | $116 | 1 payment
|
| Genentech USA | Susvimo | $90 | 4 payments
|
| Genentech | Susvimo | $85 | 2 payments
|
| Alcon Vision | Constellation | $43 | 2 payments
|
| Alimera Sciences | Iluvien | $22 | 1 payment
|
2021: $695
| Alcon Vision | Acrysof Iq Panoptix | $460 | 4 payments
|
| Genentech | None | $116 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $102 | 1 payment
|
| Genentech USA | Susvimo | $16 | 1 payment
|
2020: $613
| Alimera Sciences | Iluvien | $350 | 1 payment
|
| Genentech | Lucentis | $91 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Stellaris PC | $91 | 1 payment
|
| Alcon Vision | Constellation | $55 | 1 payment
|
| Ocular Therapeutix | Dextenza | $27 | 1 payment
|
2019: $2,588
| Alcon Vision | Dailies | $1,456 | 7 payments
|
| Regeneron Pharmaceuticals | None | $806 | 2 payments
|
| Carl Zeiss Meditec | Artevo 800 | $142 | 1 payment
|
| EyePoint Pharmaceuticals US | Dexycu | $90 | 2 payments
|
| Genentech USA | Lucentis | $70 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Stellaris PC | $24 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| F. Hoffmann-La Roche AG · Economic Benefit of Faricimab Compared To Aflibercept 8mg in Treating Patients With Neovascular Age-Related Macular Degeneration Or Diabetic Macular Edema in the United States · 2024 | This clinician | $3,047 |
| F. Hoffmann-La Roche AG · Population Impact Model of Faricimab and Aflibercept 8mg Among US Patients With Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration · 2025 | This clinician | $1,553 |
| F. Hoffmann-La Roche AG · Pigment Epithelial Detachment Thickness Fluctuations in the Archway Trial of the Port Delivery System With Ranibizumab · 2025 | This clinician | $698 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1811317357
- Licence
- CA 137610California A137610: Current · expires 2027-01-31
- Trained
- Perelman School of Med at the University of Pennsylvania, 2014 · 12 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Student in a training program (390200000X)
- Mailing address
- 10 Koret Way, Suite K302, San Francisco, CA, 94143
- NPI first listed
- 2014-04-23
- NPI last updated
- 2015-11-24
This is when the NPI record was last certified, not a medical board exam.